The efficacy of combination of induction chemotherapy and irreversible electroporation ablation for patients with locally advanced pancreatic adenocarcinoma

Kai Wen Huang, Po Chih Yang, Uei Pua, ManDeuk Kim, Sheng Ping Li, Yu Dong Qiu, Tian Qiang Song, Po Chin Liang

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background and Objectives: Irreversible electroporation (IRE) is a non-thermal focal therapy that utilizes high voltage electric pulses to permanently rupture the cellular membrane and induce cell death. In this multi-center study, we evaluated the safety and efficacy of IRE in patients with locally advanced pancreatic cancer (LAPC). Methods: From 2012 to 2015, we performed laparotomic and laparoscopic IRE in a total of 70 patients with stage III LAPC. Either gemcitabine-based or TS-1 (Tegafur, Gimeracil, and Oteracil) chemotherapy was applied for at least 3 months before the IRE. Results: No IRE-related deaths occurred. A median follow-up of 28.1 months showed that six patients (8.6%) experienced local recurrence and 24 (34%) experienced distant progression. The overall median survival from the time of treatment was 22.6 months, and the progression-free survival (PFS) was 15.4 months. The overall survival in the patients who used gemcitabine-based reagents was 19.1 months and that of those who used TS-1 was 28.7 months. The PFS for these two groups were 13.2 months and 26.4 months; the difference is significant. Conclusions: Our study suggests that IRE is safe and effective for the control of LAPC. We surmise that the addition of IRE to a chemotherapy regimen may provide a survival advantage.

Original languageEnglish
Pages (from-to)31-36
Number of pages6
JournalJournal of Surgical Oncology
Volume118
Issue number1
DOIs
Publication statusPublished - 2018 Jul 1

Fingerprint

Induction Chemotherapy
Electroporation
Combination Drug Therapy
Adenocarcinoma
gemcitabine
Pancreatic Neoplasms
Disease-Free Survival
Survival
Drug Therapy
Rupture
Cell Death
Safety
Recurrence
Membranes
Therapeutics

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology

Cite this

Huang, Kai Wen ; Yang, Po Chih ; Pua, Uei ; Kim, ManDeuk ; Li, Sheng Ping ; Qiu, Yu Dong ; Song, Tian Qiang ; Liang, Po Chin. / The efficacy of combination of induction chemotherapy and irreversible electroporation ablation for patients with locally advanced pancreatic adenocarcinoma. In: Journal of Surgical Oncology. 2018 ; Vol. 118, No. 1. pp. 31-36.
@article{f86fcfc946aa4b749f30112c2d8e4848,
title = "The efficacy of combination of induction chemotherapy and irreversible electroporation ablation for patients with locally advanced pancreatic adenocarcinoma",
abstract = "Background and Objectives: Irreversible electroporation (IRE) is a non-thermal focal therapy that utilizes high voltage electric pulses to permanently rupture the cellular membrane and induce cell death. In this multi-center study, we evaluated the safety and efficacy of IRE in patients with locally advanced pancreatic cancer (LAPC). Methods: From 2012 to 2015, we performed laparotomic and laparoscopic IRE in a total of 70 patients with stage III LAPC. Either gemcitabine-based or TS-1 (Tegafur, Gimeracil, and Oteracil) chemotherapy was applied for at least 3 months before the IRE. Results: No IRE-related deaths occurred. A median follow-up of 28.1 months showed that six patients (8.6{\%}) experienced local recurrence and 24 (34{\%}) experienced distant progression. The overall median survival from the time of treatment was 22.6 months, and the progression-free survival (PFS) was 15.4 months. The overall survival in the patients who used gemcitabine-based reagents was 19.1 months and that of those who used TS-1 was 28.7 months. The PFS for these two groups were 13.2 months and 26.4 months; the difference is significant. Conclusions: Our study suggests that IRE is safe and effective for the control of LAPC. We surmise that the addition of IRE to a chemotherapy regimen may provide a survival advantage.",
author = "Huang, {Kai Wen} and Yang, {Po Chih} and Uei Pua and ManDeuk Kim and Li, {Sheng Ping} and Qiu, {Yu Dong} and Song, {Tian Qiang} and Liang, {Po Chin}",
year = "2018",
month = "7",
day = "1",
doi = "10.1002/jso.25110",
language = "English",
volume = "118",
pages = "31--36",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "1",

}

The efficacy of combination of induction chemotherapy and irreversible electroporation ablation for patients with locally advanced pancreatic adenocarcinoma. / Huang, Kai Wen; Yang, Po Chih; Pua, Uei; Kim, ManDeuk; Li, Sheng Ping; Qiu, Yu Dong; Song, Tian Qiang; Liang, Po Chin.

In: Journal of Surgical Oncology, Vol. 118, No. 1, 01.07.2018, p. 31-36.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The efficacy of combination of induction chemotherapy and irreversible electroporation ablation for patients with locally advanced pancreatic adenocarcinoma

AU - Huang, Kai Wen

AU - Yang, Po Chih

AU - Pua, Uei

AU - Kim, ManDeuk

AU - Li, Sheng Ping

AU - Qiu, Yu Dong

AU - Song, Tian Qiang

AU - Liang, Po Chin

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Background and Objectives: Irreversible electroporation (IRE) is a non-thermal focal therapy that utilizes high voltage electric pulses to permanently rupture the cellular membrane and induce cell death. In this multi-center study, we evaluated the safety and efficacy of IRE in patients with locally advanced pancreatic cancer (LAPC). Methods: From 2012 to 2015, we performed laparotomic and laparoscopic IRE in a total of 70 patients with stage III LAPC. Either gemcitabine-based or TS-1 (Tegafur, Gimeracil, and Oteracil) chemotherapy was applied for at least 3 months before the IRE. Results: No IRE-related deaths occurred. A median follow-up of 28.1 months showed that six patients (8.6%) experienced local recurrence and 24 (34%) experienced distant progression. The overall median survival from the time of treatment was 22.6 months, and the progression-free survival (PFS) was 15.4 months. The overall survival in the patients who used gemcitabine-based reagents was 19.1 months and that of those who used TS-1 was 28.7 months. The PFS for these two groups were 13.2 months and 26.4 months; the difference is significant. Conclusions: Our study suggests that IRE is safe and effective for the control of LAPC. We surmise that the addition of IRE to a chemotherapy regimen may provide a survival advantage.

AB - Background and Objectives: Irreversible electroporation (IRE) is a non-thermal focal therapy that utilizes high voltage electric pulses to permanently rupture the cellular membrane and induce cell death. In this multi-center study, we evaluated the safety and efficacy of IRE in patients with locally advanced pancreatic cancer (LAPC). Methods: From 2012 to 2015, we performed laparotomic and laparoscopic IRE in a total of 70 patients with stage III LAPC. Either gemcitabine-based or TS-1 (Tegafur, Gimeracil, and Oteracil) chemotherapy was applied for at least 3 months before the IRE. Results: No IRE-related deaths occurred. A median follow-up of 28.1 months showed that six patients (8.6%) experienced local recurrence and 24 (34%) experienced distant progression. The overall median survival from the time of treatment was 22.6 months, and the progression-free survival (PFS) was 15.4 months. The overall survival in the patients who used gemcitabine-based reagents was 19.1 months and that of those who used TS-1 was 28.7 months. The PFS for these two groups were 13.2 months and 26.4 months; the difference is significant. Conclusions: Our study suggests that IRE is safe and effective for the control of LAPC. We surmise that the addition of IRE to a chemotherapy regimen may provide a survival advantage.

UR - http://www.scopus.com/inward/record.url?scp=85053238357&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053238357&partnerID=8YFLogxK

U2 - 10.1002/jso.25110

DO - 10.1002/jso.25110

M3 - Article

C2 - 29878378

AN - SCOPUS:85053238357

VL - 118

SP - 31

EP - 36

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 1

ER -